{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,11]],"date-time":"2026-07-11T12:17:11Z","timestamp":1783772231114,"version":"3.55.0"},"reference-count":81,"publisher":"Springer Science and Business Media LLC","license":[{"start":{"date-parts":[[2026,7,11]],"date-time":"2026-07-11T00:00:00Z","timestamp":1783728000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,7,11]],"date-time":"2026-07-11T00:00:00Z","timestamp":1783728000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"name":"National College Student Innovation and Entrepreneurship Training Program","award":["202410222018"],"award-info":[{"award-number":["202410222018"]}]},{"name":"the Heilongjiang Province Higher Education Excellent Innovation Team Basic Research Fund","award":["2023-KYYWF-0640"],"award-info":[{"award-number":["2023-KYYWF-0640"]}]},{"name":"the Heilongjiang Provincial Excellent Young Teachers Basic Research Support Program","award":["YQJH2025244"],"award-info":[{"award-number":["YQJH2025244"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin Transl Oncol"],"DOI":"10.1007\/s12094-026-04496-1","type":"journal-article","created":{"date-parts":[[2026,7,11]],"date-time":"2026-07-11T11:58:52Z","timestamp":1783771132000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Fusobacterium nucleatum, succinate signaling, and immunotherapy resistance in colorectal cancer: clinical relevance and translational opportunities"],"prefix":"10.1007","author":[{"ORCID":"https:\/\/orcid.org\/0009-0009-0077-0228","authenticated-orcid":false,"given":"Jiaqi","family":"Niu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9462-8509","authenticated-orcid":false,"given":"Weitong","family":"Sun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ruiqian","family":"Gong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qingchun","family":"Pan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,7,11]]},"reference":[{"issue":"1","key":"4496_CR1","doi-asserted-by":"publisher","first-page":"10","DOI":"10.3322\/caac.21871","volume":"75","author":"RL Siegel","year":"2025","unstructured":"Siegel RL, Kratzer TB, Giaquinto AN, et al. Cancer statistics, 2025. CA Cancer J Clin. 2025;75(1):10\u201345. https:\/\/doi.org\/10.3322\/caac.21871.","journal-title":"CA Cancer J Clin"},{"issue":"26","key":"4496_CR2","doi-asserted-by":"publisher","first-page":"2509","DOI":"10.1056\/NEJMoa1500596","volume":"372","author":"DT Le","year":"2015","unstructured":"Le DT, Uram JN, Wang H, et al. PD-1 blockade in tumors with mismatch-repair deficiency. N Engl J Med. 2015;372(26):2509\u201320. https:\/\/doi.org\/10.1056\/NEJMoa1500596.","journal-title":"N Engl J Med"},{"issue":"6","key":"4496_CR3","doi-asserted-by":"publisher","first-page":"361","DOI":"10.1038\/s41575-019-0126-x","volume":"16","author":"K Ganesh","year":"2019","unstructured":"Ganesh K, Stadler ZK, Cercek A, et al. Immunotherapy in colorectal cancer: rationale, challenges and potential. Nat Rev Gastroenterol Hepatol. 2019;16(6):361\u201375. https:\/\/doi.org\/10.1038\/s41575-019-0126-x.","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"4496_CR4","doi-asserted-by":"publisher","first-page":"1112276","DOI":"10.3389\/fonc.2023.1112276","volume":"13","author":"J Ros","year":"2023","unstructured":"Zheng HQ, Wang XX, Li J, et al. Advances in immune checkpoint inhibitor combination strategies for resistant MSS colorectal cancer. Front Oncol. 2023;13:1112276. https:\/\/doi.org\/10.3389\/fonc.2023.1112276.","journal-title":"Front Oncol"},{"key":"4496_CR5","doi-asserted-by":"publisher","first-page":"1699893","DOI":"10.3389\/fmicb.2025.1699893","volume":"16","author":"B Bai","year":"2025","unstructured":"Bai B, Ma J, Xu W, et al. Gut microbiota and colorectal cancer: mechanistic insights, diagnostic advances, and microbiome-based therapeutic strategies. Front Microbiol. 2025;16:1699893. https:\/\/doi.org\/10.3389\/fmicb.2025.1699893.","journal-title":"Front Microbiol"},{"issue":"2","key":"4496_CR6","doi-asserted-by":"publisher","first-page":"207","DOI":"10.1016\/j.chom.2013.07.007","volume":"14","author":"AD Kostic","year":"2013","unstructured":"Kostic AD, Chun E, Robertson L, et al. Fusobacterium nucleatumpotentiates intestinal tumorigenesis and modulates the tumor-immune microenvironment. Cell Host Microbe. 2013;14(2):207\u201315. https:\/\/doi.org\/10.1016\/j.chom.2013.07.007.","journal-title":"Cell Host Microbe"},{"issue":"3","key":"4496_CR7","doi-asserted-by":"publisher","first-page":"144","DOI":"10.4132\/jptm.2022.03.13","volume":"56","author":"Y Kim","year":"2022","unstructured":"Kim Y, Cho NY, Kang GH. Prognostic and clinicopathological significance of Fusobacterium nucleatum in colorectal cancer: a systemic review and meta-analysis. J Pathol Transl Med. 2022;56(3):144\u201351. https:\/\/doi.org\/10.4132\/jptm.2022.03.13.","journal-title":"J Pathol Transl Med"},{"key":"4496_CR8","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2025.1735873","volume":"16","author":"S Hu","year":"2025","unstructured":"Hu S, Heng H, Yang F, et al. The metabolism-immune axis in colorectal cancer: remodeling the tumor microenvironment through metabolite signaling. Front Immunol. 2025;16:1735873. https:\/\/doi.org\/10.3389\/fimmu.2025.1735873.","journal-title":"Front Immunol"},{"issue":"1","key":"4496_CR9","doi-asserted-by":"publisher","first-page":"2306676","DOI":"10.1080\/15384047.2024.2306676","volume":"25","author":"C Ye","year":"2024","unstructured":"Ye C, Liu X, Liu Z, et al. Fusobacterium nucleatum in tumors: from tumorigenesis to tumor metastasis and tumor resistance. Cancer Biol Ther. 2024;25(1):2306676. https:\/\/doi.org\/10.1080\/15384047.2024.2306676.","journal-title":"Cancer Biol Ther"},{"issue":"1","key":"4496_CR10","doi-asserted-by":"publisher","first-page":"2190300","DOI":"10.1080\/19490976.2023.2190300","volume":"15","author":"YH Wei","year":"2023","unstructured":"Wei YH, Ma X, Zhao JC, et al. Succinate metabolism and its regulation of host-microbe interactions. Gut Microbes. 2023;15(1):2190300. https:\/\/doi.org\/10.1080\/19490976.2023.2190300.","journal-title":"Gut Microbes"},{"issue":"7444","key":"4496_CR11","doi-asserted-by":"publisher","first-page":"238","DOI":"10.1038\/nature11986","volume":"496","author":"GM Tannahill","year":"2013","unstructured":"Tannahill GM, Curtis AM, Adamik J, et al. Succinate is an inflammatory signal that induces IL-1\u03b2 through HIF-1\u03b1. Nature. 2013;496(7444):238\u201342. https:\/\/doi.org\/10.1038\/nature11986.","journal-title":"Nature"},{"issue":"3","key":"4496_CR12","doi-asserted-by":"publisher","first-page":"539","DOI":"10.1158\/1055-9965.EPI-18-1295","volume":"29","author":"C Gethings-Behncke","year":"2020","unstructured":"Gethings-Behncke C, Coleman HG, Jordao HWT, et al. Fusobacterium nucleatum in the colorectum and its association with cancer risk and survival: a systematic review and meta-analysis. Cancer Epidemiol Biomarkers Prev. 2020;29(3):539\u201348. https:\/\/doi.org\/10.1158\/1055-9965.EPI-18-1295.","journal-title":"Cancer Epidemiol Biomarkers Prev"},{"issue":"8","key":"4496_CR13","doi-asserted-by":"publisher","first-page":"1381","DOI":"10.1007\/s10096-014-2081-3","volume":"33","author":"L Flanagan","year":"2014","unstructured":"Flanagan L, Schmid J, Ebert M, et al. Fusobacterium nucleatum associates with stages of colorectal neoplasia development, colorectal cancer and disease outcome. Eur J Clin Microbiol Infect Dis. 2014;33(8):1381\u201390. https:\/\/doi.org\/10.1007\/s10096-014-2081-3.","journal-title":"Eur J Clin Microbiol Infect Dis"},{"issue":"3","key":"4496_CR14","doi-asserted-by":"publisher","first-page":"548","DOI":"10.1016\/j.cell.2017.07.008","volume":"170","author":"T Yu","year":"2017","unstructured":"Yu T, Guo F, Yu Y, et al. Fusobacterium nucleatum Promotes Chemoresistance to Colorectal Cancer by Modulating Autophagy. Cell. 2017;170(3):548-563.e16. https:\/\/doi.org\/10.1016\/j.cell.2017.07.008.","journal-title":"Cell"},{"issue":"1","key":"4496_CR15","doi-asserted-by":"publisher","first-page":"1112","DOI":"10.1186\/s12967-025-07226-3","volume":"23","author":"K Gao","year":"2025","unstructured":"Gao K, Zhang J, Liu C, et al. Fusobacterium nucleatum enhances oxaliplatin resistance in colon cancer by increasing PVT1 expression. J Transl Med. 2025;23(1):1112. https:\/\/doi.org\/10.1186\/s12967-025-07226-3.","journal-title":"J Transl Med"},{"issue":"5","key":"4496_CR16","doi-asserted-by":"publisher","first-page":"781","DOI":"10.1016\/j.chom.2023.04.010","volume":"31","author":"SS Jiang","year":"2023","unstructured":"Jiang SS, Xie YL, Xiao XY, et al. Fusobacterium nucleatum-derived succinic acid induces tumor resistance to immunotherapy in colorectal cancer. Cell Host Microbe. 2023;31(5):781-797.e9. https:\/\/doi.org\/10.1016\/j.chom.2023.04.010.","journal-title":"Cell Host Microbe"},{"issue":"19","key":"4496_CR17","doi-asserted-by":"publisher","first-page":"9710","DOI":"10.3390\/ijms26199710","volume":"26","author":"D Incognito","year":"2025","unstructured":"Incognito D, Ciappina G, Gelsomino C, et al. Fusobacterium nucleatumin colorectal cancer: relationship among immune modulation, potential biomarkers and therapeutic implications. Int J Mol Sci. 2025;26(19):9710. https:\/\/doi.org\/10.3390\/ijms26199710.","journal-title":"Int J Mol Sci"},{"issue":"11","key":"4496_CR18","doi-asserted-by":"publisher","first-page":"1327","DOI":"10.1158\/2326-6066.CIR-18-0174","volume":"6","author":"T Hamada","year":"2018","unstructured":"Hamada T, Zhang X, Mima K, et al. Fusobacterium nucleatumin colorectal cancer relates to immune response differentially by tumor microsatellite instability status. Cancer Immunol Res. 2018;6(11):1327\u201336. https:\/\/doi.org\/10.1158\/2326-6066.CIR-18-0174.","journal-title":"Cancer Immunol Res"},{"issue":"9","key":"4496_CR19","doi-asserted-by":"publisher","first-page":"4394","DOI":"10.3390\/ijms26094394","volume":"26","author":"JA Awosika","year":"2025","unstructured":"Awosika JA, Gulley JL, Pastor DM. Deficient mismatch repair and microsatellite instability in solid tumors. Int J Mol Sci. 2025;26(9):4394. https:\/\/doi.org\/10.3390\/ijms26094394.","journal-title":"Int J Mol Sci"},{"issue":"6349","key":"4496_CR20","doi-asserted-by":"publisher","first-page":"409","DOI":"10.1126\/science.aan6733","volume":"357","author":"DT Le","year":"2017","unstructured":"Le DT, Durham JN, Smith KN, et al. Mismatch repair deficiency predicts response of solid tumors to PD-1 blockade. Science. 2017;357(6349):409\u201313. https:\/\/doi.org\/10.1126\/science.aan6733.","journal-title":"Science"},{"issue":"1","key":"4496_CR21","doi-asserted-by":"publisher","first-page":"47","DOI":"10.3393\/ac.2025.01354.0193","volume":"42","author":"SY Kim","year":"2026","unstructured":"Kim SY. Immunotherapy for microsatellite-stable colorectal cancer: overcoming resistance and exploring novel therapeutic strategies. Ann Coloproctol. 2026;42(1):47\u201357. https:\/\/doi.org\/10.3393\/ac.2025.01354.0193.","journal-title":"Ann Coloproctol"},{"issue":"1","key":"4496_CR22","doi-asserted-by":"publisher","first-page":"2544169","DOI":"10.1080\/20002297.2025.2544169","volume":"17","author":"Q Li","year":"2025","unstructured":"Li Q, Luo W, Xiao L, et al. Microbial manipulators: Fusobacterium nucleatum modulates the tumor immune microenvironment in colorectal cancer. J Oral Microbiol. 2025;17(1):2544169. https:\/\/doi.org\/10.1080\/20002297.2025.2544169.","journal-title":"J Oral Microbiol"},{"issue":"9","key":"4496_CR23","doi-asserted-by":"publisher","first-page":"1182","DOI":"10.1016\/S1470-2045(17)30422-9","volume":"18","author":"MJ Overman","year":"2017","unstructured":"Overman MJ, McDermott R, Leach JL, et al. Nivolumab in patients with metastatic DNA mismatch repair-deficient or microsatellite instability-high colorectal cancer (CheckMate 142): an open-label, multicentre, phase 2 study. Lancet Oncol. 2017;18(9):1182\u201391. https:\/\/doi.org\/10.1016\/S1470-2045(17)30422-9.","journal-title":"Lancet Oncol"},{"key":"4496_CR24","doi-asserted-by":"publisher","first-page":"1687556","DOI":"10.3389\/fmolb.2025.1687556","volume":"12","author":"AB Andac-Aktas","year":"2025","unstructured":"Andac-Aktas AB, Calibasi-Kocal G. Immunological landscape of colorectal cancer: tumor microenvironment, cellular players and immunotherapeutic opportunities. Front Mol Biosci. 2025;12:1687556. https:\/\/doi.org\/10.3389\/fmolb.2025.1687556.","journal-title":"Front Mol Biosci"},{"key":"4496_CR25","doi-asserted-by":"publisher","DOI":"10.1016\/j.neo.2022.100850","volume":"35","author":"Y Gao","year":"2023","unstructured":"Gao Y, Zou T, Xu P, et al. Fusobacterium nucleatumstimulates cell proliferation and promotes PD-L1 expression via IFIT1-related signal in colorectal cancer. Neoplasia. 2023;35:100850. https:\/\/doi.org\/10.1016\/j.neo.2022.100850.","journal-title":"Neoplasia"},{"key":"4496_CR26","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2021.658681","volume":"12","author":"L Hu","year":"2021","unstructured":"Hu L, Liu Y, Kong X, et al. Fusobacterium nucleatumfacilitates M2 macrophage polarization and colorectal carcinoma progression by activating the TLR4\/NF-\u03baB\/S100A9 cascade. Front Immunol. 2021;12:658681. https:\/\/doi.org\/10.3389\/fimmu.2021.658681.","journal-title":"Front Immunol"},{"issue":"17","key":"4496_CR27","doi-asserted-by":"publisher","first-page":"1437","DOI":"10.3390\/cells13171437","volume":"13","author":"NK Shakhpazyan","year":"2024","unstructured":"Shakhpazyan NK, Mikhaleva LM, Bedzhanyan AL, et al. Exploring the role of the gut microbiota in modulating colorectal cancer immunity. Cells. 2024;13(17):1437. https:\/\/doi.org\/10.3390\/cells13171437.","journal-title":"Cells"},{"issue":"12","key":"4496_CR28","doi-asserted-by":"publisher","first-page":"945","DOI":"10.1038\/s41568-025-00872-1","volume":"25","author":"KB Kennel","year":"2025","unstructured":"Kennel KB, Greten FR. The immune microenvironment of colorectal cancer. Nat Rev Cancer. 2025;25(12):945\u201364. https:\/\/doi.org\/10.1038\/s41568-025-00872-1.","journal-title":"Nat Rev Cancer"},{"issue":"1","key":"4496_CR29","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1158\/2326-6066.CIR-16-0297","volume":"5","author":"DI Gabrilovich","year":"2017","unstructured":"Gabrilovich DI. Myeloid-derived suppressor cells. Cancer Immunol Res. 2017;5(1):3\u20138. https:\/\/doi.org\/10.1158\/2326-6066.CIR-16-0297.","journal-title":"Cancer Immunol Res"},{"key":"4496_CR30","doi-asserted-by":"publisher","first-page":"1642091","DOI":"10.3389\/fimmu.2025.1642091","volume":"16","author":"Q He","year":"2025","unstructured":"He Q, Xiang L, Luo Y, et al. Tumor-associated macrophages in colon cancer immunotherapy: mechanisms, natural product interventions, and microenvironment remodeling. Front Immunol. 2025;16:1642091. https:\/\/doi.org\/10.3389\/fimmu.2025.1642091.","journal-title":"Front Immunol"},{"issue":"1","key":"4496_CR31","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1016\/j.ccr.2004.11.022","volume":"7","author":"MA Selak","year":"2005","unstructured":"Selak MA, Armour SM, MacKenzie ED, et al. Succinate links TCA cycle dysfunction to oncogenesis by inhibiting HIF-alpha prolyl hydroxylase. Cancer Cell. 2005;7(1):77\u201385. https:\/\/doi.org\/10.1016\/j.ccr.2004.11.022.","journal-title":"Cancer Cell"},{"issue":"9","key":"4496_CR32","doi-asserted-by":"publisher","first-page":"3812","DOI":"10.1182\/blood-2006-07-035972","volume":"109","author":"K Fischer","year":"2007","unstructured":"Fischer K, Hoffmann P, Voelkl S, et al. Inhibitory effect of tumor cell-derived lactic acid on human T cells. Blood. 2007;109(9):3812\u20139. https:\/\/doi.org\/10.1182\/blood-2006-07-035972.","journal-title":"Blood"},{"issue":"2","key":"4496_CR33","doi-asserted-by":"publisher","first-page":"313","DOI":"10.1111\/j.1742-4658.2004.04469.x","volume":"272","author":"RA Rothery","year":"2005","unstructured":"Rothery RA, Seime AM, Spiers AM, et al. Defining the Q-site of Escherichia coli fumarate reductase by site-directed mutagenesis, fluorescence quench titrations and EPR spectroscopy. FEBS J. 2005;272(2):313\u201326. https:\/\/doi.org\/10.1111\/j.1742-4658.2004.04469.x.","journal-title":"FEBS J"},{"issue":"1","key":"4496_CR34","doi-asserted-by":"publisher","first-page":"551","DOI":"10.1038\/s42003-024-06201-w","volume":"7","author":"B Udayasuryan","year":"2024","unstructured":"Udayasuryan B, Zhou Z, Ahmad RN, et al. Fusobacterium nucleatum infection modulates the transcriptome and epigenome of HCT116 colorectal cancer cells in an oxygen-dependent manner. Commun Biol. 2024;7(1):551. https:\/\/doi.org\/10.1038\/s42003-024-06201-w.","journal-title":"Commun Biol"},{"issue":"12","key":"4496_CR35","doi-asserted-by":"publisher","first-page":"1326","DOI":"10.1101\/gad.191056.112","volume":"26","author":"M Xiao","year":"2012","unstructured":"Xiao M, Yang H, Xu W, et al. Inhibition of \u03b1-KG-dependent histone and DNA demethylases by fumarate and succinate that are accumulated in mutations of FH and SDH tumor suppressors. Genes Dev. 2012;26(12):1326\u201338. https:\/\/doi.org\/10.1101\/gad.191056.112.","journal-title":"Genes Dev"},{"issue":"1","key":"4496_CR36","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1016\/j.it.2020.11.004","volume":"42","author":"G Krzak","year":"2021","unstructured":"Krzak G, Willis CM, Smith JA, et al. Succinate receptor 1: an emerging regulator of myeloid cell function in inflammation. Trends Immunol. 2021;42(1):45\u201358. https:\/\/doi.org\/10.1016\/j.it.2020.11.004.","journal-title":"Trends Immunol"},{"issue":"5","key":"4496_CR37","doi-asserted-by":"publisher","first-page":"581","DOI":"10.1038\/s41590-019-0372-7","volume":"20","author":"N Keiran","year":"2019","unstructured":"Keiran N, Ceperuelo-Mallafr\u00e9 V, Calvo E, et al. SUCNR1 controls an anti-inflammatory program in macrophages to regulate the metabolic response to obesity. Nat Immunol. 2019;20(5):581\u201392. https:\/\/doi.org\/10.1038\/s41590-019-0372-7.","journal-title":"Nat Immunol"},{"issue":"11","key":"4496_CR38","doi-asserted-by":"publisher","DOI":"10.1016\/j.celrep.2021.109246","volume":"35","author":"M Trauelsen","year":"2021","unstructured":"Trauelsen M, Hiron TK, Lin D, et al. Extracellular succinate hyperpolarizes M2 macrophages through SUCNR1\/GPR91-mediated Gq signaling. Cell Rep. 2021;35(11):109246. https:\/\/doi.org\/10.1016\/j.celrep.2021.109246.","journal-title":"Cell Rep"},{"key":"4496_CR39","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1016\/j.coi.2014.12.009","volume":"34","author":"SK Mittal","year":"2015","unstructured":"Mittal SK, Roche PA. Suppression of antigen presentation by IL-10. Curr Opin Immunol. 2015;34:22\u20137. https:\/\/doi.org\/10.1016\/j.coi.2014.12.009.","journal-title":"Curr Opin Immunol"},{"issue":"7637","key":"4496_CR40","doi-asserted-by":"publisher","first-page":"321","DOI":"10.1038\/nature21349","volume":"541","author":"DS Chen","year":"2017","unstructured":"Chen DS, Mellman I. Elements of cancer immunity and the cancer\u2013immune set point. Nature. 2017;541(7637):321\u201330. https:\/\/doi.org\/10.1038\/nature21349.","journal-title":"Nature"},{"issue":"1","key":"4496_CR41","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1186\/s12943-025-02521-5","volume":"25","author":"H Liu","year":"2025","unstructured":"Liu H, Xiong X, Zhu W, et al. Gut microbial metabolites in cancer immunomodulation. Mol Cancer. 2025;25(1):8. https:\/\/doi.org\/10.1186\/s12943-025-02521-5.","journal-title":"Mol Cancer"},{"issue":"3","key":"4496_CR42","doi-asserted-by":"publisher","first-page":"472","DOI":"10.3390\/cancers16030472","volume":"16","author":"BD Griffith","year":"2024","unstructured":"Griffith BD, Frankel TL. The aryl hydrocarbon receptor: impact on the tumor immune microenvironment and modulation as a potential therapy. Cancers (Basel). 2024;16(3):472. https:\/\/doi.org\/10.3390\/cancers16030472.","journal-title":"Cancers (Basel)"},{"key":"4496_CR43","doi-asserted-by":"publisher","first-page":"1375905","DOI":"10.3389\/fonc.2024.1375905","volume":"14","author":"KA Chaudhry","year":"2024","unstructured":"Chaudhry KA, Bianchi-Smiraglia A. The aryl hydrocarbon receptor as a tumor modulator: mechanisms to therapy. Front Oncol. 2024;14:1375905. https:\/\/doi.org\/10.3389\/fonc.2024.1375905.","journal-title":"Front Oncol"},{"issue":"5","key":"4496_CR44","doi-asserted-by":"publisher","first-page":"653","DOI":"10.1001\/jamaoncol.2015.1377","volume":"1","author":"K Mima","year":"2015","unstructured":"Mima K, Sukawa Y, Nishihara R, et al. Fusobacterium nucleatum and T cells in colorectal carcinoma. JAMA Oncol. 2015;1(5):653\u201361. https:\/\/doi.org\/10.1001\/jamaoncol.2015.1377.","journal-title":"JAMA Oncol"},{"issue":"12","key":"4496_CR45","doi-asserted-by":"publisher","first-page":"1973","DOI":"10.1136\/gutjnl-2015-310101","volume":"65","author":"K Mima","year":"2016","unstructured":"Mima K, Nishihara R, Qian ZR, et al. Fusobacterium nucleatum in colorectal carcinoma tissue and patient prognosis. Gut. 2016;65(12):1973\u201380. https:\/\/doi.org\/10.1136\/gutjnl-2015-310101.","journal-title":"Gut"},{"issue":"6371","key":"4496_CR46","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1126\/science.aan3706","volume":"359","author":"B Routy","year":"2018","unstructured":"Routy B, Le Chatelier E, Derosa L, et al. Gut microbiome influences efficacy of PD-1-based immunotherapy against epithelial tumors. Science. 2018;359(6371):91\u20137. https:\/\/doi.org\/10.1126\/science.aan3706.","journal-title":"Science"},{"issue":"2","key":"4496_CR47","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1016\/j.molcel.2019.10.023","volume":"77","author":"JY Wu","year":"2020","unstructured":"Wu JY, Huang TW, Hsieh YT, et al. Cancer-derived succinate promotes macrophage polarization and cancer metastasis via succinate receptor. Mol Cell. 2020;77(2):213-227.e5. https:\/\/doi.org\/10.1016\/j.molcel.2019.10.023.","journal-title":"Mol Cell"},{"issue":"1","key":"4496_CR48","doi-asserted-by":"publisher","first-page":"1878","DOI":"10.1186\/s12885-025-15433-w","volume":"25","author":"Y Yi","year":"2025","unstructured":"Yi Y, Cao Y, Guo Y, et al. Serum untargeted metabolomics analysis of colorectal cancer. BMC Cancer. 2025;25(1):1878. https:\/\/doi.org\/10.1186\/s12885-025-15433-w.","journal-title":"BMC Cancer"},{"issue":"51","key":"4496_CR49","doi-asserted-by":"publisher","first-page":"18321","DOI":"10.1073\/pnas.1406199111","volume":"111","author":"CM Dejea","year":"2014","unstructured":"Dejea CM, Wick EC, Hechenbleikner EM, et al. Microbiota organization is a distinct feature of proximal colorectal cancers. Proc Natl Acad Sci USA. 2014;111(51):18321\u20136. https:\/\/doi.org\/10.1073\/pnas.1406199111.","journal-title":"Proc Natl Acad Sci USA"},{"issue":"7937","key":"4496_CR50","doi-asserted-by":"publisher","first-page":"810","DOI":"10.1038\/s41586-022-05435-0","volume":"611","author":"JL Galeano Ni\u00f1o","year":"2022","unstructured":"Galeano Ni\u00f1o JL, Wu H, LaCourse KD, et al. Effect of the intratumoral microbiota on spatial and cellular heterogeneity in cancer. Nature. 2022;611(7937):810\u20137. https:\/\/doi.org\/10.1038\/s41586-022-05435-0.","journal-title":"Nature"},{"key":"4496_CR51","doi-asserted-by":"publisher","DOI":"10.1136\/gutjnl-2025-338000","author":"ZW Zhong","year":"2026","unstructured":"Zhong ZW, Lu YQ, Duan Y, et al. Fusobacterium nucleatum in cancer: from bystander to driver. Gut. 2026. https:\/\/doi.org\/10.1136\/gutjnl-2025-338000.","journal-title":"Gut"},{"issue":"3","key":"4496_CR52","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1038\/nrmicro1838","volume":"6","author":"PS Stewart","year":"2008","unstructured":"Stewart PS, Franklin MJ. Physiological heterogeneity in biofilms. Nat Rev Microbiol. 2008;6(3):199\u2013210. https:\/\/doi.org\/10.1038\/nrmicro1838.","journal-title":"Nat Rev Microbiol"},{"key":"4496_CR53","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1016\/j.jprot.2018.12.029","volume":"195","author":"J Liu","year":"2019","unstructured":"Liu J, Hsieh CL, Gelincik O, et al. Proteomic characterization of outer membrane vesicles from gut mucosa-derived Fusobacterium nucleatum. J Proteomics. 2019;195:125\u201337. https:\/\/doi.org\/10.1016\/j.jprot.2018.12.029.","journal-title":"J Proteomics"},{"issue":"1","key":"4496_CR54","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1016\/j.cell.2014.03.011","volume":"157","author":"Y Belkaid","year":"2014","unstructured":"Belkaid Y, Hand TW. Role of the microbiota in immunity and inflammation. Cell. 2014;157(1):121\u201341. https:\/\/doi.org\/10.1016\/j.cell.2014.03.011.","journal-title":"Cell"},{"issue":"8","key":"4496_CR55","doi-asserted-by":"publisher","first-page":"1131","DOI":"10.3748\/wjg.v11.i8.1131","volume":"11","author":"A Swidsinski","year":"2005","unstructured":"Swidsinski A, Loening-Baucke V, Lochs H, et al. Spatial organization of bacterial flora in normal and inflamed intestine: a fluorescence in situ hybridization study in mice. World J Gastroenterol. 2005;11(8):1131\u201340. https:\/\/doi.org\/10.3748\/wjg.v11.i8.1131.","journal-title":"World J Gastroenterol"},{"key":"4496_CR56","doi-asserted-by":"publisher","DOI":"10.1016\/j.ebiom.2023.104670","volume":"93","author":"X Kang","year":"2023","unstructured":"Kang X, Ng SK, Liu C, et al. Altered gut microbiota of obesity subjects promotes colorectal carcinogenesis in mice. EBioMedicine. 2023;93:104670. https:\/\/doi.org\/10.1016\/j.ebiom.2023.104670.","journal-title":"EBioMedicine"},{"issue":"3","key":"4496_CR57","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1080\/19490976.2015.1134082","volume":"7","author":"DJ Morrison","year":"2016","unstructured":"Morrison DJ, Preston T. Formation of short-chain fatty acids by the gut microbiota and their impact on human metabolism. Gut Microbes. 2016;7(3):189\u2013200. https:\/\/doi.org\/10.1080\/19490976.2015.1134082.","journal-title":"Gut Microbes"},{"issue":"1","key":"4496_CR58","doi-asserted-by":"publisher","first-page":"1776","DOI":"10.1186\/s12885-025-15094-9","volume":"25","author":"J Xu","year":"2025","unstructured":"Xu J, Song J, Fu Z, Zhou H, Zhang Y, Shi C. Unraveling gut microbiome interferences in cancer immunotherapy: a meta-analysis of diverse drug effects. BMC Cancer. 2025;25(1):1776. https:\/\/doi.org\/10.1186\/s12885-025-15094-9.","journal-title":"BMC Cancer"},{"issue":"13","key":"4496_CR59","doi-asserted-by":"publisher","first-page":"2228","DOI":"10.3390\/cancers17132228","volume":"17","author":"G Ciappina","year":"2025","unstructured":"Ciappina G, Ottaiano A, Santorsola M, et al. Impact of proton pump inhibitor use on progression-free and overall survival in cancer patients undergoing immune checkpoint inhibitor therapy: a systematic review and meta-analysis of recent studies. Cancers (Basel). 2025;17(13):2228. https:\/\/doi.org\/10.3390\/cancers17132228.","journal-title":"Cancers (Basel)"},{"key":"4496_CR60","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2020.01153","volume":"11","author":"D Maseda","year":"2020","unstructured":"Maseda D, Ricciotti E. NSAID\u2013gut microbiota interactions. Front Pharmacol. 2020;11:1153. https:\/\/doi.org\/10.3389\/fphar.2020.01153.","journal-title":"Front Pharmacol"},{"issue":"6","key":"4496_CR61","doi-asserted-by":"publisher","DOI":"10.3390\/microorganisms13061410","volume":"13","author":"M Cintoni","year":"2025","unstructured":"Cintoni M, Palombaro M, Zoli E, et al. The interplay between the gut microbiota and colorectal cancer: a review of the literature. Microorganisms. 2025;13(6):1410. https:\/\/doi.org\/10.3390\/microorganisms13061410.","journal-title":"Microorganisms"},{"issue":"4","key":"4496_CR62","doi-asserted-by":"publisher","first-page":"e0298924","DOI":"10.1128\/mbio.02989-24","volume":"16","author":"JP Connolly","year":"2025","unstructured":"Connolly JP, Kelly L. The physical biogeography of Fusobacterium nucleatum in health and disease. MBio. 2025;16(4):e0298924. https:\/\/doi.org\/10.1128\/mbio.02989-24.","journal-title":"MBio"},{"issue":"6","key":"4496_CR63","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0269541","volume":"17","author":"A Aitchison","year":"2022","unstructured":"Aitchison A, Pearson JF, Purcell RV, et al. Detection of Fusobacterium nucleatum DNA in primary care patient stool samples does not predict progression of colorectal neoplasia. PLoS ONE. 2022;17(6):e0269541. https:\/\/doi.org\/10.1371\/journal.pone.0269541.","journal-title":"PLoS ONE"},{"issue":"1","key":"4496_CR64","doi-asserted-by":"publisher","first-page":"162","DOI":"10.1186\/s12935-026-04245-y","volume":"26","author":"S Zhang","year":"2026","unstructured":"Zhang S, Fu Q, Yuan X, et al. Reshaping the colorectal cancer immune microenvironment: insights from single-cell and spatial omics. Cancer Cell Int. 2026;26(1):162. https:\/\/doi.org\/10.1186\/s12935-026-04245-y.","journal-title":"Cancer Cell Int"},{"issue":"6","key":"4496_CR65","doi-asserted-by":"publisher","first-page":"1512","DOI":"10.1038\/s41588-025-02193-3","volume":"57","author":"MF Oliveira","year":"2025","unstructured":"Oliveira MF, Romero JP, Chung M, et al. High-definition spatial transcriptomic profiling of immune cell populations in colorectal cancer. Nat Genet. 2025;57(6):1512\u201323. https:\/\/doi.org\/10.1038\/s41588-025-02193-3.","journal-title":"Nat Genet"},{"key":"4496_CR66","doi-asserted-by":"publisher","first-page":"1634703","DOI":"10.3389\/fphar.2025.1634703","volume":"16","author":"M Hao","year":"2025","unstructured":"Hao M, Xu H, Li M, Jiao D. The role and challenges of intratumoral microbiota in colorectal cancer immunotherapy. Front Pharmacol. 2025;16:1634703. https:\/\/doi.org\/10.3389\/fphar.2025.1634703.","journal-title":"Front Pharmacol"},{"key":"4496_CR67","doi-asserted-by":"publisher","first-page":"1652702","DOI":"10.3389\/fmicb.2025.1652702","volume":"16","author":"X He","year":"2025","unstructured":"He X, Zhao Q, Zhang J, et al. Potential and application of Fusobacterium nucleatum in the diagnosis and treatment of colorectal cancer. Front Microbiol. 2025;16:1652702. https:\/\/doi.org\/10.3389\/fmicb.2025.1652702.","journal-title":"Front Microbiol"},{"issue":"23","key":"4496_CR68","doi-asserted-by":"publisher","DOI":"10.3390\/ijms262311319","volume":"26","author":"Y Seo","year":"2025","unstructured":"Seo Y, Kim KA, Lee S, et al. A Duplex qPCR assay targeting the fadA gene enables robust detection of Fusobacterium in clinical samples. Int J Mol Sci. 2025;26(23):11319. https:\/\/doi.org\/10.3390\/ijms262311319.","journal-title":"Int J Mol Sci"},{"issue":"1","key":"4496_CR69","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1007\/s10495-025-02239-1","volume":"31","author":"S Chen","year":"2026","unstructured":"Chen S, Wang Z, Sun P, Liu Y. Succinate-mediated SUCNR1 activation in tumor-associated macrophages promotes M2 polarization and cetuximab resistance in colorectal cancer: in vitro and in vivo insights. Apoptosis. 2026;31(1):22. https:\/\/doi.org\/10.1007\/s10495-025-02239-1.","journal-title":"Apoptosis"},{"issue":"1","key":"4496_CR70","doi-asserted-by":"publisher","first-page":"70","DOI":"10.1186\/s13027-025-00676-w","volume":"20","author":"AS Kowsarkhizi","year":"2025","unstructured":"Kowsarkhizi AS, Yousefi B, Rahimi A, Aliramezani A. Targeting Fusobacterium nucleatum in colorectal cancer: therapeutic strategies and future directions. Infect Agents Cancer. 2025;20(1):70. https:\/\/doi.org\/10.1186\/s13027-025-00676-w.","journal-title":"Infect Agents Cancer"},{"issue":"1","key":"4496_CR71","doi-asserted-by":"publisher","first-page":"45","DOI":"10.3390\/antibiotics14010045","volume":"14","author":"HYP Lam","year":"2025","unstructured":"Lam HYP, Lai MJ, Wang PC, et al. A Novel bacteriophage with the potential to inhibit Fusobacterium nucleatum-induced proliferation of colorectal cancer cells. Antibiotics. 2025;14(1):45. https:\/\/doi.org\/10.3390\/antibiotics14010045.","journal-title":"Antibiotics"},{"issue":"Pt 2","key":"4496_CR72","doi-asserted-by":"publisher","DOI":"10.1016\/j.jconrel.2025.114400","volume":"388","author":"T Wu","year":"2025","unstructured":"Wu T, Zhang F, Liu H, et al. Fusobacterium nucleatum-targeted polymeric micelles disrupting biofilm-immune crosstalk for precision colorectal cancer immunotherapy. J Control Release. 2025;388(Pt 2):114400. https:\/\/doi.org\/10.1016\/j.jconrel.2025.114400.","journal-title":"J Control Release"},{"issue":"1","key":"4496_CR73","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1038\/s41522-025-00717-7","volume":"11","author":"J Queen","year":"2025","unstructured":"Queen J, Cing Z, Minsky H, et al. Fusobacterium nucleatum is enriched in invasive biofilms in colorectal cancer. NPJ Biofilms Microbiomes. 2025;11(1):81. https:\/\/doi.org\/10.1038\/s41522-025-00717-7.","journal-title":"NPJ Biofilms Microbiomes"},{"key":"4496_CR74","doi-asserted-by":"publisher","first-page":"424","DOI":"10.1038\/s41586-024-07182-w","volume":"628","author":"M Zepeda-Rivera","year":"2024","unstructured":"Zepeda-Rivera M, Minot SS, Bouzek H, et al. A distinct Fusobacterium nucleatum clade dominates the colorectal cancer niche. Nature. 2024;628:424\u201332. https:\/\/doi.org\/10.1038\/s41586-024-07182-w.","journal-title":"Nature"},{"key":"4496_CR75","doi-asserted-by":"publisher","DOI":"10.1016\/j.crmicr.2025.100414","volume":"9","author":"M Wolf","year":"2025","unstructured":"Wolf M, Steinberg T, Scholz KJ, et al. The rise and evolving role of Fusobacterium nucleatum subspecies. Curr Res Microb Sci. 2025;9:100414. https:\/\/doi.org\/10.1016\/j.crmicr.2025.100414.","journal-title":"Curr Res Microb Sci"},{"key":"4496_CR76","doi-asserted-by":"publisher","DOI":"10.3389\/fmolb.2026.1815835","volume":"13","author":"AD Liebing","year":"2026","unstructured":"Liebing AD, St\u00e4ubert C. Sensing succinate: SUCNR1 as a context-dependent metabolic and cellular signal integrator. Front Mol Biosci. 2026;13:1815835. https:\/\/doi.org\/10.3389\/fmolb.2026.1815835.","journal-title":"Front Mol Biosci"},{"issue":"3","key":"4496_CR77","doi-asserted-by":"publisher","first-page":"564","DOI":"10.1016\/j.ccell.2025.02.023","volume":"43","author":"X Wang","year":"2025","unstructured":"Wang X, Fang Y, Liang W, et al. Fusobacterium nucleatumfacilitates anti-PD-1 therapy in microsatellite-stable colorectal cancer. Cancer Cell. 2025;43(3):564\u201374. https:\/\/doi.org\/10.1016\/j.ccell.2025.02.023.","journal-title":"Cancer Cell"},{"issue":"1","key":"4496_CR78","doi-asserted-by":"publisher","first-page":"2458203","DOI":"10.1080\/19490976.2025.2458203","volume":"17","author":"C Duizer","year":"2025","unstructured":"Duizer C, Salomons M, van Gogh M, et al. Fusobacterium nucleatum upregulates the immune inhibitory receptor PD-L1 in colorectal cancer cells via the activation of ALPK1. Gut Microbes. 2025;17(1):2458203. https:\/\/doi.org\/10.1080\/19490976.2025.2458203.","journal-title":"Gut Microbes"},{"key":"4496_CR79","doi-asserted-by":"publisher","first-page":"1629014","DOI":"10.3389\/fimmu.2025.1629014","volume":"16","author":"R Heregger","year":"2025","unstructured":"Heregger R, Huemer F, Greil R, et al. Impact of Fusobacterium nucleatum on immune cell functions in colorectal cancer. Front Immunol. 2025;16:1629014. https:\/\/doi.org\/10.3389\/fimmu.2025.1629014.","journal-title":"Front Immunol"},{"key":"4496_CR80","doi-asserted-by":"publisher","first-page":"1795703","DOI":"10.3389\/fimmu.2026.1795703","volume":"17","author":"W Wuyi","year":"2026","unstructured":"Wuyi W, Pan T. Microbe-driven immune suppression in colorectal cancer: the Fusobacterium nucleatum playbook. Front Immunol. 2026;17:1795703. https:\/\/doi.org\/10.3389\/fimmu.2026.1795703.","journal-title":"Front Immunol"},{"key":"4496_CR81","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1186\/s12943-025-02566-6","volume":"25","author":"D Yan","year":"2026","unstructured":"Yan D, Yu Y, Liang C, et al. Intratumoral microbiome: the double-edged sword in remodeling cancer immunotherapy. Mol Cancer. 2026;25:43. https:\/\/doi.org\/10.1186\/s12943-025-02566-6.","journal-title":"Mol Cancer"}],"container-title":["Clinical and Translational Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12094-026-04496-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12094-026-04496-1","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12094-026-04496-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,11]],"date-time":"2026-07-11T11:58:54Z","timestamp":1783771134000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12094-026-04496-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,11]]},"references-count":81,"alternative-id":["4496"],"URL":"https:\/\/doi.org\/10.1007\/s12094-026-04496-1","relation":{},"ISSN":["1699-3055"],"issn-type":[{"value":"1699-3055","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,11]]},"assertion":[{"value":"23 March 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 June 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 July 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare that they have no conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"No persons or animals were involved in this review.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}}]}}